Colorectal Cancer
Mainz Biomed Stock Spikes on Positive Data for mRNA-Enhanced Colorectal Cancer Screening Assay
In top-line data, Mainz Biomed's enhanced ColoAlert detected CRC with 94 percent sensitivity and 97 percent specificity, and advanced adenoma with 81 percent sensitivity.
DoMore Diagnostics, Proscia Ink Collaboration on Colorectal Cancer Histopathology Testing
The digital pathology firms will combine their technologies to help pathologists predict patient outcomes and incorporate AI-supported decision-making.
The company said it expects to launch a first version of its residual cancer test, OncoDetect, by the end of this year, while ongoing studies explore newer technology.
Epigenomics to Sell Patents, Biobank to New Day Diagnostics
Epigenomics will receive up to about $12.1 million in cash, milestone payments, and a small stake in New Day Diagnostics.
Guardant Health MRD Test Garners Coverage From Blue Cross, Blue Shield of Louisiana
The payor has initiated coverage of Guardant Reveal, a liquid biopsy test for detection and monitoring of residual cancer in patients with stage II and III colon cancer.